BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33789628)

  • 1. Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study.
    Kim SR; Hong JH; Sung SY; Kim YH; Chun SH; Lee HW; Lee JS; Ko YH
    BMC Cancer; 2021 Mar; 21(1):340. PubMed ID: 33789628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
    Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Outcomes of 9,994 Patients With Extensive-Disease Small-Cell Lung Cancer From a Retrospective Nationwide Population-Based Cohort in the Korean HIRA Database.
    Lee JS; Kim S; Sung SY; Kim YH; Lee HW; Hong JH; Ko YH
    Front Oncol; 2021; 11():546672. PubMed ID: 33828968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of EP Chemotherapy Followed by IP Chemotherapy Combined with Radiotherapy in the Treatment of Extensive-Stage Small-Cell Lung Cancer.
    Kang S; Lai CORXWZJHYZDCJ
    J BUON; 2021; 26(2):306-312. PubMed ID: 34076973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide.
    Karam I; Jiang SY; Khaira M; Lee CW; Schellenberg D
    Am J Clin Oncol; 2015 Feb; 38(1):51-4. PubMed ID: 23563211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
    Senan S; Okamoto I; Lee GW; Chen Y; Niho S; Mak G; Yao W; Shire N; Jiang H; Cho BC
    Clin Lung Cancer; 2020 Mar; 21(2):e84-e88. PubMed ID: 31948903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [First-line chemotherapy and its survival analysis of 394 patients with extensive-stage small cell lung cancer in a single institute].
    Ma M; Wang M; Xu Y; Hu K; Liu H; Li L; Zhong W; Zhang L; Zhao J; Wang H
    Zhongguo Fei Ai Za Zhi; 2014 Jan; 17(1):8-14. PubMed ID: 24398308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis of limited-stage small cell lung cancer with comprehensive treatment including radical resection.
    Zhong L; Suo J; Wang Y; Han J; Zhou H; Wei H; Zhu J
    World J Surg Oncol; 2020 Feb; 18(1):27. PubMed ID: 32013993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Concurrent Chemoradiotherapy with Original Chemotherapy Regimens may not be Suitable for Patients Who Failed to Respond to Induction Chemotherapy
in Limited-stage Small Cell Lung Cancer].
    Wang D; Xu L; Zhao L; Zhang W; Pang Q; Liu N; Chen X; Chen X; Yuan Z; Wang P
    Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):871-878. PubMed ID: 27978874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation 
with Concurrent Twice-daily Radiotherapy for Patients 
with Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
    Xenidis N; Kotsakis A; Kalykaki A; Christophyllakis Ch; Giassas S; Kentepozidis N; Polyzos A; Chelis L; Vardakis N; Vamvakas L; Georgoulias V; Kakolyris S
    Lung Cancer; 2010 Jun; 68(3):450-4. PubMed ID: 19783319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial.
    Wang C; Zhu S; Miao C; Wang Y; Chen J; Yuan S; Hu X
    BMC Cancer; 2022 May; 22(1):542. PubMed ID: 35562713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential Versus Concurrent Chemoradiation Therapy by Surgical Margin Status in Resected Non-Small Cell Lung Cancer.
    Verma V; Moreno AC; Haque W; Fang P; Lin SH
    J Natl Compr Canc Netw; 2018 May; 16(5):508-516. PubMed ID: 29752325
    [No Abstract]   [Full Text] [Related]  

  • 15. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center.
    Shrimali RK; Nallathambi C; Saha A; Das A; Prasath S; Mahata A; Arun B; Mallick I; Achari R; Dabkara D; Thambudorai R; Chatterjee S
    Indian J Cancer; 2018; 55(2):125-133. PubMed ID: 30604722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and efficacy of simultaneous integrated boost intensity-modulated radiation therapy in patients with limited-disease small cell lung cancer.
    Han D; Qin Q; Hao S; Huang W; Wei Y; Zhang Z; Wang Z; Li B
    Radiat Oncol; 2014 Dec; 9():280. PubMed ID: 25498196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study.
    Zhao S; Chen K; Shi X; Sun J; Fang W; Huang Y; Zhang L
    Clin Lung Cancer; 2023 Nov; 24(7):e254-e258. PubMed ID: 37442748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy 
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
    Huang C; Zhu Y; Li Q; Zhang W; Liu H; Zhang W; Hu Y; Yuan Y; Liu M
    Cancer Med; 2019 Jan; 8(1):28-39. PubMed ID: 30600600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.